Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048684 | 0.91 | CYP1A2 (0.46) | CYP2D6CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4325779 | 0.80 | HRH3 (0.54) | HRH1GBA1HRH3HRH4LOXL2 | |
| SCHEMBL3681167 | 0.78 | HRH3 (0.49) | HRH1GBA1HRH3HRH4 | |
| SCHEMBL4708456 | 0.76 | HRH3 (0.51) | CYP2D6GBA1HRH3HRH4LOXL2 | |
| SCHEMBL27747846 | 0.73 | KEAP1 (0.36) | HRH1HRH3KEAP1NFE2L2LOXL2 | |
| SCHEMBL10774121 | 0.73 | HRH3 (0.43) | HRH1HRH3HRH4 | |
| SCHEMBL2109582 | 0.72 | GBA1 (0.66) | CYP2D6GBA1HRH3HRH4HPGD | |
| Hydrochloric Acid SCHEMBL1550607 | 0.71 | GBA1 (0.63) | CYP2D6GBA1HRH3HRH4 | |
| SCHEMBL387442 | 0.70 | KEAP1 (0.48) | KEAP1NFE2L2 | |
| SCHEMBL5052270 | 0.70 | NMT1 (0.40) | CYP2D6CYP3A4CYP2C9HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |